Seminars in dialysis
-
Seminars in dialysis · Jan 2009
ReviewHemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
Anemia management in hemodialysis patients has progressed following the introduction of erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron. However, maintaining a stable hemoglobin (Hb) level can be challenging. ⋯ Fluctuating Hb levels is associated with increased complications. This article reviews factors that affect Hb control, with a focus on management practices (e.g., regular low-dose administration of IV iron) that can help improve anemia management.